On the evening of October 22, Tigermed released the third quarter report, during the reporting period, the company achieved operating income of 1.339 billion yuan, an increase of 57.77% year-on-year; achieved a net profit of 526 million yuan, an increase of 64.80% year-on-year. In the first three quarters, the company achieved revenue of 3.395 billion yuan, an increase of 47.58% year-on-year; achieved a net profit of 1.781 billion yuan, an increase of 35.13% year-on-year.
As of the end of the third quarter, the CEIBS Healthcare Hybrid Fund, managed by star fund manager Glen, ranked the company's fourth largest circulating shareholder, compared with 1.3821 million shares in the previous period, while Hillhouse and Central Huijin withdrew from the list of the top ten circulating shareholders.
Provide clinical research solutions
According to public information, Tigermed is engaged in providing professional services for the whole process of clinical trials for new drug research and development, providing comprehensive and comprehensive clinical research solutions for global pharmaceutical and medical device innovation enterprises, and its main business includes clinical trial technical services, clinical trial related services and laboratory services.
It is worth noting that the company achieved a net profit of 799 million yuan in the second quarter. Based on this calculation, the net profit in the third quarter fell by 34.17% sequentially.
Screenshot from Wind
Tigermed said that during the reporting period, Tigermed continued to strengthen its own innovation and industrial cooperation, independently developed a risk-based quality management (RBQM) system online, using digital technology to empower clinical development; and reached strategic cooperation with jiuzhou pharmaceutical and other partners, E-Site excellent clinical research center strategy to rapidly promote, jointly build an industrial innovation ecology, help and accelerate pharmaceutical innovation.
Cao Xiaochun, president of Tigermed, said that in the third quarter of 2021, while continuing to maintain steady growth, the company continued to improve the integrated service capabilities of clinical research and the international layout to maintain and enhance the competitiveness of the industry. In the future, the company will further consolidate and expand the service capabilities and scale, promote the strategies of internationalization, digitalization and innovation drive, tap the great potential of tigermed new drug life cycle R&D service platform, and work with global innovation partners to accelerate the process of new drug research and development, seek the well-being of patients, and contribute to the cause of global health.
Glenga Warehouse
According to the third quarterly report, as of September 30, the number of shareholders of the company reached 39,000, and the per capita shareholding amount was 3.0652 million yuan. The total shareholding ratio of the top ten circulating shareholders is 53.15%, and the chips are relatively dispersed; the shareholding ratio of institutional investors among shareholders is 30.55%, down from 55.25% at the end of the second quarter.
It is worth noting that the CeIBS Medical and Health Hybrid Fund managed by star fund manager Glen ranked as the fourth largest circulating shareholder, compared with 13.6942 million shares in the previous period, with a change ratio of 85.15%; Hillhouse and Central Huijin withdrew from the list of the top ten circulating shareholders, and at the end of the second quarter, Hillhouse's shareholding was 7.5 million shares, while the threshold for the top ten circulating shareholders at the end of the third quarter was 7.988 million shares. The second largest shareholder, Hong Kong Securities Clearing Company Limited (Lu Stock Connect), reduced its holdings, holding 94.1084 million shares, accounting for 13.71%.
List of the top ten outstanding shareholders at the end of the third quarter
List of the top ten outstanding shareholders at the end of the second quarter
Screenshot from Oriental Fortune
In terms of stock price performance, the company's stock price has fluctuated greatly this year, out of two "V" shapes, the highest rise to 209.41 yuan per share, the lowest to 120.1 yuan per share. As of the close of trading on October 22, Tigermed reported 164.02 yuan per share, with a total market value of 143.1 billion yuan.
Recent moves have been frequent
On August 25, 2021, the Company deliberated and passed the "Proposal on the Plan to Repurchase the Company's Shares", which plans to repurchase shares with its own funds or self-raised funds, with a total of 250 million yuan to 500 million yuan of repurchased shares, and the repurchase price does not exceed 190 yuan per share, and the repurchased shares will be used as a follow-up equity incentive plan or employee stock ownership plan.
According to the third quarterly report, as of the end of the reporting period, the company's share repurchase special securities account has repurchased 2.6992 million shares of the company's shares in a centralized auction transaction, accounting for 0.3094% of the total share capital, with the highest transaction price of 128.15 yuan -160 yuan / share, and the total transaction amount is 363 million yuan (excluding transaction costs).
In terms of personnel changes, on August 10, 2021, the company hired Wu Hao, who has 17 years of experience in the pharmaceutical industry and former general manager of Maxim Insurance Brokers (Shanghai) Co., Ltd., as the co-president of the company, and the term of office is from the date of deliberation and approval of the board of directors to the expiration date of the fourth board of directors, after which Wu Hao was elected as a director of the company and a member of the strategy committee of the board of directors of the company.
On September 17, Jun Gao (Gao Jun), deputy general manager, head of finance and secretary of the board of directors of the company, resigned for personal reasons and no longer holds any position in the company after resignation. Cao Xiaochun, the controlling shareholder, one of the actual controllers and the general manager of the company, took over as the person in charge of the company's finance, appointed Li Xiaori, the former representative of the company's securities affairs, as the secretary of the company's board of directors, and appointed Ruan Xinhui as the representative of the company's securities affairs, and the term of office was from the date of deliberation and approval of the 19th meeting of the fourth board of directors of the company to the date of expiration of the term of office of the fourth board of directors.
This article originated from China Securities News